# US 2026/0308163 A1 · Crystalline forms of a parp1 inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0308163 A1
- Document ID: US20260308163A1
- Status: Published application
- Kind: A1
- Application number: 19/428,821
- Filed: 2025-12-22
- Published: 2026-10-08
- Earliest claimed: 2024-12-24
- Assignees: Gilead Sciences, Inc.
- Applicants: Gilead Sciences, Inc.
- Inventors: Jing Liu; Jayachandra P. Reddy; Stefani Kocevska
- Web page: https://patentgrep.com/patent/US20260308163A1

## CPC

- C07D 491/048: the oxygen-containing ring being five-membered
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to salts and solid forms of a compound that are inhibitors of PARP and their uses as therapeutic agents for treating diseases, such as cancer.

## Claims

### Claim 1

A crystalline form of Compound I:
(Compound I Form I), wherein Compound I Form I is characterized by an X-ray powder diffractogram comprising peaks (±0.2°) at 8.1, 9.4, and 19.7 °2θ as determined on a diffractometer using Cu-Kα radiation.

### Claim 2 (depends on 1)

The crystalline form of claim 1, further characterized by:
i) one or more peaks at (±0.2°) at 4, 12.2, or 18.8 °2θ;
ii) a diffractogram substantially as shown in FIG. 1A;
iii) a differential scanning calorimetry (DSC) curve comprising an endotherm at about 285° C. (onset temperature);
iv) a differential scanning calorimetry (DSC) curve substantially as shown in FIG. 1B;
v) thermogravimetric analysis (TGA) showing a weight loss of about 0.5 wt % up to about 65° C.;
vi) thermogravimetric analysis (TGA) comprising a thermogram substantially as shown in FIG. 1B; or
vii) a dynamic vapor sorption (DVS) curve showing about 1.04% water uptake at 80% relative humidity (RH) or about 1.19% water uptake at 90% RH; or
viii) a DVS curve substantially as shown in FIG. 1C.

### Claim 3

A crystalline form of Compound I:
(Compound I Form II), wherein Compound I Form II is characterized by an X-ray powder diffractogram comprising peaks (±0.2°) at 6.4, 9.1, and 18.7 °2θ as determined on a diffractometer using Cu-Kα radiation.

### Claim 4 (depends on 3)

The crystalline form of claim 3, further characterized by:
i) one or more peaks at (±0.2°) at 9.7, 14.1, or 19.5 °2θ;
ii) a diffractogram substantially as shown in FIG. 2A;
iii) a differential scanning calorimetry (DSC) curve comprising an endotherm at about 159° C. (onset temperature) and an endotherm at about 287° C. (onset temperature);
iv) a differential scanning calorimetry (DSC) curve substantially as shown in FIG. 2B;
v) thermogravimetric analysis (TGA) showing a weight loss of about 7.6 wt % up to about 185° C.; or
vi) thermogravimetric analysis (TGA) comprising a thermogram substantially as shown in FIG. 2B.

### Claim 5

A crystalline form of Compound I:
(Compound I Form III), wherein Compound I Form III is characterized by an X-ray powder diffractogram comprising peaks (±0.2°) at 4.7, 9.5, and 12.6 °2θ as determined on a diffractometer using Cu-Kα radiation.

### Claim 6 (depends on 5)

The crystalline form of claim 5, further characterized by:
i) one or more peaks at (±0.2°) at 7.5, 11.7, or 18.3 °2θ;
ii) a diffractogram substantially as shown in FIG. 3A;
iii) a differential scanning calorimetry (DSC) curve comprising an endotherm at about 268° C. (onset temperature) and an endotherm at about 281° C. (onset temperature);
iv) a differential scanning calorimetry (DSC) curve substantially as shown in FIG. 3B;
v) thermogravimetric analysis (TGA) showing a weight loss of about 1.2 wt % up to about 290° C.;
vi) thermogravimetric analysis (TGA) comprising a thermogram substantially as shown in FIG. 3B;
vii) a dynamic vapor sorption (DVS) curve showing about 0.77% water uptake at 80% RH or about 1.13% at 90% RH; or
viii) a DVS curve substantially as shown in FIG. 3C.

### Claim at position 7

7-76. (canceled)

### Claim 77 (depends on 1)

A pharmaceutical composition comprising the crystalline form of claim 1, and a pharmaceutically acceptable excipient.

### Claim 78 (depends on 1)

A method of treating cancer in a subject in need thereof, the method comprising administering the crystalline form of claim 1.

### Claim 79 (depends on 78)

The method of claim 78, wherein the cancer is breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, a hematological cancer, gastrointestinal cancer, or lung cancer.

### Claim 80 (depends on 1)

A method of treating a cancer comprising a BRCA1 and/or a BRCA2 mutation in a subject in need thereof, the method comprising administering the crystalline form of claim 1.

### Claim 81 (depends on 80)

The method of claim 80, wherein the cancer is bladder cancer, brain & CNS cancers, breast cancer, cervical cancer, colorectal cancer, esophagus cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, kidney cancer, leukemia, lung cancer, melanoma, myeloma, oral cavity cancer, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, thyroid cancer, or uterus cancer.
